Wells Fargo raised the firm’s price target on Regeneron (REGN) to $800 from $745 and keeps an Equal Weight rating on the shares. The firm found the company’s commentary around Dupixent intellectual property extension encouraging. It sees upside to 2026 estimates, but says Regeneron shares lack catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $769 from $768 at Morgan Stanley
- Balanced Risk/Reward Keeps Regeneron at Hold Amid Solid Fundamentals and Pipeline Uncertainty
- Regeneron’s Earnings Call: Growth Engines and Rising Costs
- Regeneron Pharmaceuticals: Robust 4Q25 Beat, Underappreciated Pipeline Upside, and 2026 Catalysts Support Buy Rating and $870 Target
- Regeneron price target raised to $870 from $820 at Raymond James